A phase I study was conducted to test the safety of a new drug among healthy subjects. Because the new drug is primarily cleared kidney. renal clearance of a biomarker is used as an indicator of kidney function. The researchers compared the clearance of the biomarker between subjects who received the new drug and those receiving the placebo. The statistical results are presented in the Tables below. Treatment N Mean Std. Deviation Std. Error Mean Clearance Placebo 15 1.21 0.32 .08 New drug 15 1.49 0.45 .12 Levene's Test for . 9? 5% CI of the Equalrly of ttest for Means Difference Variances . Sig. (2 Mean F 5'9' l m tailed) Difference Lm' \"pp" Equal \"3mm\" 1.553 0.209 -1 .35? 23 mm o.2?533 41.62653 nurses assumed Eq\""' \"\"3\"\"5 1 .35? 23.956 mm: 4.1.3533 41.62991 9.0?924 not assumed Based on information in the tables. what type of s:atistical analysis was performed? 0 Chi-square test O One-way ANOVA O Twoway AN OVA O Independent(unpaired}ttest O Paired ttest